Navigation Links
Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
Date:12/10/2008

ANSS total score.

In the 53-week non-inferiority trial, patients were randomly assigned to receive flexible dose paliperidone palmitate plus orally supplemented placebo (PP+Pbo) or flexible dose risperidone LAT plus orally supplemented risperidone (LAT RIS+RIS). All injections were administered in the gluteal muscle. Patients in the PP+Pbo group received two 50 mg eq. injections one week apart, followed by injections of 25, 50, 75 or 100 mg eq. every 4 weeks. Patients in the LAT RIS+RIS group received a placebo injection on day 1, 25 mg risperidone LAT on days 8 and 22 and injections every 2 weeks of 25, 37.5 or 50 mg. The primary endpoint was the change in PANSS total score from baseline to endpoint. Non-inferiority was planned to be demonstrated if paliperidone palmitate was no worse than risperidone LAT, as measured by a 95% confidence interval of more than -5 points in the change in PANSS total score.

Although patients receiving both paliperidone palmitate and risperidone LAT had similar improvements in PANSS scores at the end of the 53 week trial, the difference between paliperidone palmitate and risperidone LAT in the least square adjusted mean change in PANSS score was -2.6 points, with a 95% confidence interval (CI) of (-5.84, 0.61). As the lower limit (-5.84) of the CI was less than -5, non-inferiority of paliperidone palmitate versus risperidone LAT was not demonstrated using this dosing regimen. Comparative plasma concentrations of paliperidone in the PP+Pbo group were consistently lower than concentrations of active moiety in the LAT RIS+RIS group until day 260. Although non-inferiority was not demonstrated using this dosing regimen, it is not possible to conclude superiority of LAT RIS+RIS over PP+Pbo using the results from this study. Overall rates of adverse events were similar in both groups: 76% for paliperidone palmitate and 79% for risperidone LAT. The most common (>10% in either group) TE
'/>"/>

SOURCE Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
3. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
4. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
5. AcelRx Pharmaceuticals Reports Positive Results From a Phase 2 Clinical Trial of Sublingual Sufentanil NanoTabs(TM) in Treating Post-Operative Pain
6. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
7. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. SemBioSys begins phase I/II trial of insulin produced in plant seeds
10. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
11. OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... the 63rd Annual Meeting of the American Society ... 100 mg/day or,150 mg/day of desvenlafaxine, a serotonin ... in moderate to severe,vasomotor symptoms (VMS) (hot flashes ...
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide ... third quarter 2007 financial results on,Thursday, November 1, ... hosting a,conference call and webcast to discuss the ... Management will discuss financial results for the third ...
... Technique to be Presented at American ... Meeting -, - Improved Techniques Could Lead to ... well as PGD with In Vitro Fertilization -, ... developing high throughput technologies that enable genome-wide,analyses, and Reprogenetics, ...
Cached Biology Technology:Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 2Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 3Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 4Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo 5Orchid Cellmark to Announce Third Quarter 2007 Financial Results on November 1, 2007 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis (PGD) 3
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research ... announced the addition of the "Global Facial ... http://photos.prnewswire.com/prnh/20130307/600769 ... the identification of individuals. Facial recognition system measures ... as nose, jaw edges, mouth, and the distance ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... A new study by the Wildlife Conservation Society, ... that habitat fragmentation and the addition of makeshift perches ... preferred habitat for common ravens that threaten sensitive ... The study appears in the January issue of the ...
... Renewable Energy Laboratory (NREL) have discovered that an enzyme from ... the Kamchatka Peninsula in Russia in 1990 can digest cellulose ... enzyme on the market. If the enzyme continues to ... the price of making lignocellulosic fuels, from ethanol to other ...
... 2014 -- Although drugs have been developed that inhibit the ... which causes many brain disorders and nervous system diseases ... work has not yet been fully explained. Now, ... as a model, have deciphered the mode by which the ...
Cached Biology News:Might more ravens -- aided by humans -- mean 'nevermore' for sage-grouse? 2Might more ravens -- aided by humans -- mean 'nevermore' for sage-grouse? 3NREL finds a new cellulose digestion mechanism by a fast-eating enzyme 2NREL finds a new cellulose digestion mechanism by a fast-eating enzyme 3Neurotransmitters resarch can promote better drugs for brain disorders 2Neurotransmitters resarch can promote better drugs for brain disorders 3
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: